{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:33:30Z","timestamp":1786649610633,"version":"build-2736575974"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The efficacy and safety of once-daily fixed-dose combination of indacaterol maleate (IND) 110 \u00b5g with glycopyrronium 25 \u00b5g (GLY) via Rotahaler device versus tiotropium (TRP) 9 \u00b5g + formoterol (FOR) 112 \u00b5g was evaluated in patients with chronic obstructive airway disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      (1) To study and compare the effect of inhaled IND\/GLY (110\/50 \u00b5g) once-daily (OD) fixed-dose combination versus FOR\/TRP (9\/12 \u00b5g) twice daily (BD) on lung function in chronic obstructive pulmonary disease (COPD) patients by evaluating forced expiratory volume in 1 s (FEV1), 1 h postinhalation on days 28\n                      <jats:sup>th<\/jats:sup>\n                      , 56\n                      <jats:sup>th<\/jats:sup>\n                      , and 84\n                      <jats:sup>th<\/jats:sup>\n                      of the treatment. (2) To assess patient-reported outcomes (PROs) using COPD assessment test (CAT) scores, intake of rescue medications, and frequency of exacerbations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      In this prospective observational comparative study, patients were randomly assigned in a 1:1 ratio to two sequences: sequence 1 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 50) receiving IND\/GLY (110\/50 \u00b5g) once daily and sequence 2 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 50) receiving TRP\/FOR (9\/12 \u00b5g) twice daily. The evaluation of postinhalation FEV1 at 1 h after treatment was conducted on days 28, 56, and 84.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result:<\/jats:title>\n                    <jats:p>Patients in the IND\/GLY sequence showed significantly higher FEV1, 1 h postinhalation than those in TRP\/FOR. A higher proportion of the patients stated that they were very satisfied with IND\/GLY versus TRP\/FOR about dyspnea reduction and showed a significant improvement in CAT score. IND\/GLY demonstrated a good safety and tolerability profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study indicated that, beyond FEV1, important PROs as well as lung function improved with the use of long-acting IND\/GLY combination when compared with TRP\/FOR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aam.aam_120_24","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T11:00:09Z","timestamp":1748689209000},"page":"636-642","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["To Study the Safety and Efficacy of Fixed Dose Combination of Indacaterolmaleate 110 \u00b5g + Glycopyrrinium 50 \u00b5g versus Tiotropium 9 \u00b5g + Formoterol 12 \u00b5g in Patients with Chronic Obstructive Airway Disease"],"prefix":"10.4103","volume":"24","author":[{"given":"Javeeria","family":"Shabbir","sequence":"first","affiliation":[{"name":"Department of Respiratory Diseases, Jawaharlal Nehru Medical College and Hospital, AMU, Aligarh, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imrana","family":"Masood","sequence":"additional","affiliation":[{"name":"Department of TB and Respiratory Diseases, Jawaharlal Nehru Medical College and Hospital, AMU, Aligarh, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shah Mohd Abbas","family":"Waseem","sequence":"additional","affiliation":[{"name":"Department of Physiology, Jawaharlal Nehru Medical College and Hospital, AMU, Aligarh, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Yusuf","family":"Masood","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis, Jawaharlal Nehru Medical College and Hospital, AMU, Aligarh, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"R1-20260422","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1164\/rccm.202204-0671PP","article-title":"Definition and nomenclature of chronic obstructive pulmonary disease: Time for its revision","volume":"206","author":"Celli","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"R2-20260422","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S2213-2600(21)00555-5","article-title":"Pathogenesis of chronic obstructive pulmonary disease: Understanding the contributions of gene-environment interactions across the lifespan","volume":"10","author":"Agust\u00ed","year":"2022","journal-title":"Lancet Respir Med"},{"key":"R3-20260422","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(07)61377-4","article-title":"International variation in the prevalence of COPD (the BOLD study): A population-based prevalence study","volume":"370","author":"Buist","year":"2007","journal-title":"Lancet"},{"key":"R4-20260422","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.pupt.2010.03.003","article-title":"The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD","volume":"23","author":"Cazzola","year":"2010","journal-title":"Pulm Pharmacol Ther"},{"key":"R5-20260422","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A 4-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N Engl J Med"},{"key":"R6-20260422","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1021\/jm100068m","article-title":"The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist","volume":"53","author":"Baur","year":"2010","journal-title":"J Med Chem"},{"key":"R7-20260422","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1358\/dot.2010.46.3.1450070","article-title":"Indacaterol for chronic obstructive pulmonary disease (COPD)","volume":"46","author":"Cazzola","year":"2010","journal-title":"Drugs Today (Barc)"},{"key":"R8-20260422","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2466-14-4","article-title":"A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: The GLOW5 study","volume":"14","author":"Chapman","year":"2014","journal-title":"BMC Pulm Med"},{"key":"R9-20260422","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/15412555.2021.1894111","article-title":"Efficacy and safety of inhaled glycopyrronium bromide in COPD: A randomized, parallel group, dose-ranging study (GLIMMER)","volume":"18","author":"Kerwin","year":"2021","journal-title":"COPD"},{"key":"R10-20260422","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.chest.2016.11.028","article-title":"Efficacy and safety of glycopyrrolate\/FOR metered dose inhaler formulated using co-suspension delivery technology in patients with COPD","volume":"151","author":"Martinez","year":"2017","journal-title":"Chest"},{"key":"R11-20260422","first-page":"345","article-title":"Comparative study of pulmonary functions and oxidative stress in smokers and non-smokers","volume":"56","author":"Waseem","year":"2012","journal-title":"Indian Journal of Physiology and Pharmacology"}],"container-title":["Annals of African Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_120_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:56:01Z","timestamp":1786647361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_120_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/aam.aam_120_24","relation":{},"ISSN":["1596-3519","0975-5764"],"issn-type":[{"value":"1596-3519","type":"print"},{"value":"0975-5764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"2024-07-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}